Group 1 - The core viewpoint of the articles is that the next-generation "in vivo CAR-T" technology is rapidly emerging, potentially addressing the high costs and accessibility issues associated with traditional CAR-T therapies [1][2]. - Traditional CAR-T therapy involves extracting a patient's T cells, modifying them in a lab, and reinfusing them, which is time-consuming and expensive, often exceeding 1 million yuan per treatment [1]. - In vivo CAR-T technology allows for direct modification of T cells within the patient's body using carriers like viruses or lipid nanoparticles, significantly simplifying the process and reducing costs [2]. Group 2 - The cost of in vivo CAR-T therapy is expected to drop to one-tenth of traditional methods, greatly enhancing accessibility for patients [2]. - The treatment process for in vivo CAR-T can yield results in as little as three days with just one or two intravenous injections, compared to the weeks required for traditional CAR-T [2]. - As the technology matures, patients may receive effective and durable cell therapies through simple injections, potentially expanding the range of treatable diseases and lowering overall medical costs [3].

Core Insights - The in vivo CAR-T therapy market is rapidly gaining traction, with significant mergers and acquisitions by major multinational corporations (MNCs) indicating a strategic shift towards this innovative treatment approach [1][2][3] - The advancements in delivery vector technologies are driving the development of in vivo CAR-T therapies, with a focus on improving targeting efficiency and safety [3][4] Group 1: Mergers and Acquisitions - AstraZeneca acquired EsoBiotec for $1 billion to enhance its in vivo CAR-T therapy portfolio [1][2] - AbbVie announced the acquisition of Capstan Therapeutics for up to $2.1 billion, marking a significant investment in the in vivo CAR-T space [1][2] - Gilead's Kite acquired Interius for $350 million, further expanding its capabilities in cell therapy [1][2] Group 2: Technology Platforms - EsoBiotec's core technology is the engineered nanobody lentivirus (ENaBL) platform, which enhances the specificity of immune cell transfection [4] - Interius utilizes a lentiviral vector to deliver CAR genes, generating CAR-T and CAR-NK cells directly in vivo for targeting B-cell malignancies [3][4] - The mRNA-LNP (lipid nanoparticle) delivery system is gaining attention for its safety profile, allowing for transient CAR expression without permanent genetic modification [7][8] Group 3: Clinical Developments - EsoBiotec's product ESO-T01 has shown promising clinical trial results for multiple myeloma, indicating potential effectiveness in treating relapsed or refractory cases [15][17] - Capstan Therapeutics' candidate CPTX2309 is currently in Phase I trials for autoimmune diseases, showcasing the therapeutic potential of the LNP delivery approach [8][9] Group 4: Industry Trends - The shift from ex vivo to in vivo CAR-T therapies is reshaping the ecosystem, with increased collaboration among technology partners and a focus on delivery efficiency [3][6] - The reliance on upstream CXO (Contract Research Organization) services is significant, with over 65% of CGT (Cell and Gene Therapy) projects involving CXO participation [6][12] - The industry is witnessing a dual approach, with companies like AbbVie investing in both lentiviral and mRNA-LNP technologies to mitigate risks associated with single technology pathways [16][17]